Skip Navigation

European Heart Journal 1997 18(Supplement C):33-39; doi:10.1093/eurheartj/18.suppl_C.33
Copyright © 1997 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cobbe, S. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Cobbe, S. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1997 The European Society of Cardiology

Using the right drug

A treatment algorithm for atrial fibrillation

S. M. Cobbe

Royal Infirmary 10 Alexandra Parade, Glasgow, U.K.

Correspondence: Stuart M. Cobbe, Walton Professor of Medical Cardiology, Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, U.K.

Atrial fibrillation is the commonest sustained cardiac arrhythmia. Its incidence increases with age and in association with organic heart disease, in particular valvular heart disease, left ventricular dysfunction and in association with thyrotoxicosis and alcohol excess. Atrial fibrillation may present as paroxysms of self-terminating arrhythmia or as a sustained arrhythmia. In the former instance, management is directed towards suppression of paroxysms and will commonly involve class 1C, class 2 or class 3 agents. If atrial fibrillation is sustained, a decision as to the desirability of cardioversion must be made. If this can be acheived successfully, particularly if the episode was of brief duration and associated with a reversible cause, sinus rhythm may be preserved without further antiarrhythmic therapy. Otherwise prophylactic therapy as used for paroxysmal atrial fibrillation is appropriate. In patients who fail to respond to cardioversion, or in those with advanced organic heart disease, long-standing atrial fibrillation or marked dilatation of the left atrium in which case cardioversion is unlikely to be successful, the principal therapeutic strategy is to control ventricular rate. Classically, digoxin is used for this purpose. Additional agents which will slow the ventricular rates, such as beta-blockers, amiodarone or calcium channel antagonists (verapamil or diltiazem), may be necessary if the ventricular rate remains uncontrolled and continues to produce severe symptoms. In the event of failure of medical therapy to control ventricular rate, atrioventricular nodal modification or ablation may be appropriate.

Key Words: Atrial fibrillation • arrhythmia • digoxin • beta-blockers


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama
Impact of Drug Transporter Studies on Drug Discovery and Development
Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.